
Avanos Medical AVNS
$ 13.65
1.87%
Annual report 2025
added 02-24-2026
Avanos Medical General and Administrative Expenses 2011-2026 | AVNS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 316 M | 318 M | 335 M | 326 M | 300 M | 333 M | 399 M | 340 M | 322 M | 411 M | 398 M | 424 M | 351 M | 343 M | 352 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 424 M | 300 M | 351 M |
Quarterly General and Administrative Expenses Avanos Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.6 M | 83.5 M | 75.7 M | - | 74.3 M | 80.9 M | 83.6 M | - | 78.7 M | 93 M | 88.8 M | - | 78.3 M | 83.2 M | 90.1 M | - | 75 M | 76.7 M | 73.4 M | - | 82.4 M | 76.9 M | 91.1 M | - | 94.4 M | 94.7 M | 106 M | - | 86.3 M | 79.8 M | 86.4 M | - | 78.4 M | 81.1 M | 84.8 M | - | 100 M | 108 M | 92.8 M | - | 97.2 M | 106 M | 97.2 M | - | 111 M | 101 M | 85.5 M | - | 82.5 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 111 M | 73.4 M | 87.5 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.35 | - | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
554 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
LENSAR
LNSR
|
26.5 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
44.6 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
132 M | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Penumbra
PEN
|
663 M | $ 334.17 | -0.41 % | $ 13 B | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
39.3 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
3.24 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
10.3 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
138 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
14 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
22.5 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
37.9 M | $ 3.53 | -2.35 % | $ 53.7 K | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 52.07 | -0.17 % | $ 1.53 B | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.31 | -5.76 % | $ 53.3 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Sensus Healthcare
SRTS
|
7.87 M | $ 3.96 | -3.65 % | $ 64.7 M | ||
|
InspireMD
NSPR
|
20.7 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
634 M | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M |